Jun. 2 at 12:53 AM
Among micro-cap biotech names,
$NSRX has been attracting growing attention.
The company's lead candidate, NS002, is a needle-free intranasal epinephrine powder designed for the
$2B+ anaphylaxis treatment market, offering a potential alternative to traditional injectable products.
Reported Phase 2 results showed:
• Median time to therapeutic levels: 1.69 minutes
• EpiPen comparison: 3.42 minutes
• 91% reached therapeutic concentration within 5 minutes
• No serious adverse events reported
Beyond NS002, the company is advancing multiple pipeline candidates.
Key milestones investors are watching include:
• IND submission expected in Q3 2026
• Pivotal study planned for Q4 2026
• Potential data readout around Q1 2027
The company also completed a
$15M private financing earlier this year to support clinical development.
With a market capitalization of roughly
$60M, future valuation changes will likely depend on clinical execution, regulatory progress, and upcoming trial results.
